Hematopoietic Stem Cell Therapy in Autoimmune Diseases

REVIEW ARTICLE

Conference Synopsis: Hematopoietic Stem Cell Therapy in Autoimmune Diseases, October 2001

Biology of Blood and Marrow Transplantation 8:407-411 (2002)
© 2002 American Society for Blood and Marrow Transplantation

ABSTRACT:

Since 1996, patients with autoimmune diseases have been treated on single-arm investigational protocols with highdose immunosuppressive therapy and autologous peripheral blood stem cell transplantation (HSCT). In a conference held in October 2001 at the City of Hope National Medical Center, participants discussed current laboratory studies in autoimmunity, the rationale of HSCT in autoimmune diseases, results of phase I-II studies, and the prospects for controlled trials. This conference synopsis summarizes major discussion points in clinical sessions and in sessions devoted to ethical and regulatory aspects of this investigational treatment. Protocols for controlled studies in multiple sclerosis (MS) and systemic sclerosis (SSc), originating in Europe and in the United States, have been designed or are in the final stages of design. The only controlled trial presently underway is for SSc in Europe (Autologous Stem Cell Transplantation International Scleroderma Trial [ASTIS]). There are current plans for a controlled trial for rheumatoid arthritis (RA) in Europe (ASTIRA) but not in the United States. Eventual crossstudy analysis of the European and United States trials may give valuable comparative information on the different mobilization and immunosuppressive regimens used. Recognition of the importance of axonal degeneration in secondary progressive MS and the use of mitoxantrone as a rescue medication are two relatively recent developments now being considered in the design of controlled HSCT protocols in MS. The importance of informed consent and study accessibility was discussed as well as the continuing role of the US Food and Drug Administration in regulating these protocols in the United States.

Download a PDF version of the full article

Copyright 1995-2010 - Carden Jennings Publishing Co., Ltd. All rights reserved. The material available at this site is for educational purposes only and is NOT intended for any diagnostic, clinically related, or other purpose. Carden Jennings Publishing Co., Ltd., assumes no responsibility for any use or misuse of this material and makes no warranty or representation of any kind with respect to the material available at this site.

Featured Resources Multiple Myeloma: A Practical Guide to Current Management BloodLine Image Atlas